Edition:
India

Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

14.90USD
2:29am IST
Change (% chg)

$-1.15 (-7.17%)
Prev Close
$16.05
Open
$16.05
Day's High
$16.17
Day's Low
$14.30
Volume
84,424
Avg. Vol
39,419
52-wk High
$24.25
52-wk Low
$10.50

Latest Key Developments (Source: Significant Developments)

Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

Deerfield Management Reports 10 Pct Passive Stake In Melinta Therapeutics
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Melinta Therapeutics Inc ::DEERFIELD MANAGEMENT COMPANY LP REPORTS A 10 PCT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN 5 - SEC FILING.  Full Article

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

‍Melinta Therapeutics, Cempra name Daniel Wechsler as CEO of combined company
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cempra Inc :‍Melinta Therapeutics says co, Cempra announced that their selection committee selected Dan Wechsler to be president and CEO of combined company​.  Full Article

Cempra appoints David Zaccardelli as acting CEO
Monday, 12 Dec 2016 

Cempra Inc : Cempra inc - appointed board member David Zaccardelli, pharm.d., as acting chief executive officer . Cempra inc - promoted David Moore to newly created position of president and chief commercial officer, effective immediately .Cempra appoints David Zaccardelli as acting chief executive officer, promotes chief commercial officer David Moore to president.  Full Article

Cempra says FDA scheduled meeting to discuss safety, efficacy of solithromycin
Tuesday, 30 Aug 2016 

Cempra Inc :FDA scheduled meeting of Antimicrobial Drugs Advisory Committee on Nov. 4 to discuss safety, efficacy of solithromycin.  Full Article

Cempra says current cash, equivalents sufficient to fund ongoing operations through 2017
Tuesday, 2 Aug 2016 

Cempra Inc : Cempra reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.51 .Cempra Inc says current cash and equivalents are expected to be sufficient to fund ongoing operations through 2017.  Full Article

Cempra announces positive data from Japenese study on solithromycin
Thursday, 26 May 2016 

Cempra Inc :Cempra announces successful results in the phase 2 community acquired bacterial pneumonia (cabp) trial conducted by japanese partner, toyama chemical (a subsidiary of fujifilm holdings corporation).  Full Article

BRIEF-Melinta Therapeutics Files For Resale Of Up To 6.9 Mln Shares By Selling Stockholders

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 6.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2EqugN6) Further company coverage: